Clinical Laboratory Services Latam

Today, advances in molecular diagnostics, personalized medicine, and biomedical technology have given physicians unprecedented insight into the biology of disease. Yet this progress has created a new challenge: the growing complexity of diagnostic decision-making. Physicians face an expanding universe of tests, platforms, and biomarkers, making it hard to determine the right test for a specific clinical question and interpret the results correctly. What they increasingly need is not simply a laboratory that generates data, but a diagnostic partner capable of transforming complex findings into clinically meaningful answers.

Meeting this need has been at the heart of MediPath’s mission for the past two decades. By combining advanced molecular diagnostics, pathology expertise, research, and physician collaboration, it has built an integrated diagnostic model designed to support more informed clinical decisions across Latin America.

“We see ourselves as a diagnostic partner, not just a testing provider,” says Argelia Aybar, medical director and founder. “Our pathologists work with physicians to discuss cases, explain testing capabilities, help identify the most appropriate tests and interpret results with confidence.”

From Advanced Testing to Clinical Decision Support

Founded in 2004 in the Dominican Republic, MediPath emerged during a period when many advanced molecular pathology capabilities were not available locally and specialized samples often had to be sent abroad. Its mission was to bring sophisticated diagnostic solutions closer to physicians and patients while developing the expertise to interpret these technologies locally. The organization expanded its capabilities in response to challenges identified by physicians—beginning with HPV DNA testing, followed by liquid-based cytology with ThinPrep, immunohistochemistry, flow cytometry, real-time PCR, and additional molecular diagnostic applications.

When a physician orders a genetic test, the report that comes back rarely settles anything on its own. It lists findings but does not clarify which ones matter for this patient, how to explain the results to a family still in the room, or what the next clinical step should be. That interpretive gap is where diagnoses stall and care decisions drift without firm ground. Cligen, a medical genetics clinic founded in Vitória, Brazil, in 2021, was built to close that gap.

“We are a clinic before we are a laboratory,” says Dr. Arsonval Lamounier Júnior, medical director. “We place the patient and their family at the center of our approach.”

That orientation changes what a physician receives. Every genetic report arrives with a clinical case interpretation. The Cligen team reviews the findings, evaluates the literature relevant to the presentation and calls the referring physician directly. The effect is that, instead of filing the report, deferring to a specialist, or delaying a care decision, the clinician gains a colleague ready to reason through the result in real time. That conversation is what turns a genetic finding into a clinical action.

Cligen also maps its referring network, recognizing that physicians vary widely in their comfort with genetics. Those working near the limits of their genomic training receive targeted education, invitations to scientific meetings and direct collaboration on complex cases. As clinicians gain confidence, they order more appropriate tests, interpret results more accurately and deliver better care. Each interaction strengthens the network’s collective genomic literacy.

The same logic shapes Cligen’s test portfolio. Rather than offering an overwhelming catalog, the clinic curates high-quality, certified assays with broad gene coverage, organized by clinical presentation. The diagnostic strategy follows the clinical question, ensuring that the right test reaches the right patient without delay.

What Blood Could Not Show

Cligen’s approach matters most when a case resists resolution. A newborn presented with bilateral epibulbar ocular tumors and cutaneous lesions arranged along the lines of Blaschko, sharply respecting the midline. Whole exome sequencing on peripheral blood had returned negative. Without a different strategy, the child’s condition would have remained undiagnosed and no clear clinical path forward existed.

Barnafi Krause Laboratory (BKLAB) combines deep expertise in genetic testing and precision medicine with hands-on experience in next-generation sequencing (NGS). Dedicated to serving clinical laboratories, clinics, and hospitals across Latin America, BKLAB delivers highly complex tests with accuracy and reliability.

From its earliest years, BKLAB has focused on adopting advanced tools and techniques while continuously monitoring global scientific developments. The team reviews international studies and the work of leading centers to identify technologies worth implementing, and evaluates each innovation carefully before integrating it into the laboratory’s workflows.

For sequencing, BKLAB relies on Illumina platforms supported by advanced bioinformatics solutions from Golden Helix (Bozeman, MT). This commitment is reinforced by ongoing improvements in pre-analytical and analytical processes and continuous training for its technical and support staff.

“Our advanced technology, together with our specialized teams, guarantees excellence in every process,” says Andrea Barnafi, CEO of BKLAB.

Belonging to international quality networks is a cornerstone of BKLAB’s approach. These affiliations provide objective evidence that its processes meet the highest technical and legal standards.

It collaborates with the College of American Pathologists (CAP), the European Molecular Genetics Network (EMQN), and the European Research Initiative on CLL (ERIC) and participates in congresses such as ADML. The laboratory will also present a poster at the American Society of Human Genetics (ASHG) in Boston in 2025.

BKLAB’s work is powered by next-generation sequencing, real-time PCR, and mass spectrometry. These technologies, combined with the expertise of its specialized teams, ensure accuracy and reliability. The laboratory also participates in international intercomparison programs, which serve as quality benchmarks and as opportunities to validate its practices on a global stage.

Founded in 2019 and headquartered in Guatemala City, BIOTI has positioned itself at the forefront of preventive cancer diagnostics and genetic testing in Latin America.

Co-founded by Dr. Sebastián Yurrita, director of the genetic laboratory and expert in human genetics and genomics, the company has redefined how early detection and precision medicine are delivered across the region. By harnessing cutting-edge technologies and tailoring solutions to the unique challenges of Latin American healthcare systems, BIOTI has built a reputation for innovation, accessibility, and life-saving impact. To achieve this, BIOTI is leveraging advanced genetic testing and molecular diagnostics to detect cancer years before tumors develop.

“By revealing cancer early and guiding the right treatment, we give patients peace of mind, better survival chances, and protection from the crushing costs of late-stage care,” says Yurrita.

The results of early detection speak volumes. BIOTI’s advanced genetic techniques can even project risks decades into the future, enabling physicians to select the most effective drug therapies for each unique case. Another hallmark of the company’s work is the breadth of its diagnostic capabilities. BIOTI offers more than 800 different genetic tests that cover fields ranging from oncology and pediatrics to cardiology, neurology, endocrinology, rheumatology, gynecology, and nutrition.

Rather than relying on years of trial-and-error diagnostics, it enables physicians to identify a patient’s condition with a single comprehensive test. This saves valuable time, reduces healthcare costs, and allows for rapid, accurate treatment. Importantly, BIOTI has also made affordability a core part of its mission, recognizing that equitable access to genetic testing is essential in a region where healthcare inequality remains a pressing challenge.

The Latin American molecular pathology lab industry is increasing at a steady pace, as healthcare institutions continue to embrace the development of sophisticated diagnostics technologies and laboratory improvements. The increase in the need for accurate diagnosis, combined with developments in technology and clinical requirements, has ensured that molecular pathology plays an essential role in healthcare development.

From hospitals and research facilities to diagnostic centers, there is an increasing awareness of the need to capitalize on laboratory services as a business asset because they increase efficiency and facilitate decision-making. This is a changing environment in which laboratories can take advantage and grow sustainably within the regional health care market.

Strengthening Laboratory Infrastructure through Technological Advancement

Molecular pathology laboratories in Latin America have been consistently making significant investments in innovative technologies, which help increase the accuracy of testing, as well as improve the efficiency and quality of laboratory work. With the implementation of state-of-the-art diagnostic equipment, automation of work processes, and the use of laboratory information management systems, it becomes possible to carry out work faster while maintaining the same high-quality standards.

The development of infrastructure goes beyond acquiring equipment, focusing on the design of laboratories, optimizing workflow and implementing quality management systems to facilitate day-to-day activities. A well-designed laboratory environment facilitates efficiency in handling of samples, management of information and reporting while eliminating unneeded complexity. With the increased demand for diagnostic services, businesses require scalable laboratory infrastructures for future expansion.

Workforce development investments still matter as much as ever in maintaining high laboratory performance standards. Laboratory technicians, technical experts, and quality management teams play an important role in sustaining good operations through continued learning. By educating employees, organizations ensure that technical know-how is strengthened and laboratories stay in line with scientific standards.

Digitization helps with the improvement of operations through the monitoring of key performance indicators, managing laboratory workflow, and maintaining documentation. The increased accessibility of data ensures better coordination within laboratory departments and also assists with making informed decisions about capacity planning, resource allocation, and expansion of services.

Building Sustainable Business Models through Quality and Compliance

The concept of quality assurance forms the bedrock of molecular pathology laboratory activities in Latin America. The use of standardized operating procedures, internal quality control, and continuous performance monitoring plays an integral role in ensuring that the laboratories achieve consistency through the various stages of the process, thereby assuring the various partners who interact with them.

It is also important to be compliant because laboratory operations are set against different national healthcare environments. Documenting processes, validated analyses and recording operations ensures compliance while at the same time enabling partnerships with healthcare facilities and research establishments. Organizations that are always making sure they are capable of being compliant build up their competitive advantage.

The creation of strategic alliances is another way of enhancing sustainable business development within the field of molecular pathology. Strategic alliances between laboratories, academic organizations, health care organizations, and other research organizations lead to knowledge sharing and innovation while improving services. Through strategic alliances, laboratories are able to grow technically, access services, and adapt to changing health care needs.

Sustainable finance is also influenced by effective operations management, which includes resource optimization, staffing, and investments. Those labs that combine sustainable finance with quality management form sustainable models that can facilitate their growth in a highly competitive healthcare industry environment.

Expanding Market Opportunities across Regional Healthcare Systems

The ongoing process of modernizing healthcare services across Latin America offers ideal circumstances for molecular pathology labs wishing to expand their business. With rising awareness about diagnostic capabilities, healthcare organizations are driven towards adopting laboratory services in their overall clinical strategy, thereby creating a perpetual need for quality diagnostics. Businesses that are aware of the healthcare needs in the region have a better chance of offering services accordingly.

Integration of technology helps the company expand its market reach through enhanced communication within the labs, healthcare practitioners, and institutions with which the company collaborates. The use of digital reporting systems, improved information management systems, and better coordination of workflow improves the quality of services provided as well as client satisfaction.

Market growth is becoming more dependent on the balance between science and efficiency. Labs with technology, staff expertise, quality management systems, and service strategies centered on the customer will have an easier time competing in various healthcare settings. Such a balanced strategy allows companies to deal with changes in market dynamics and sustain their performance.

Molecular pathology laboratories throughout Latin America can only hope to see an improvement in their performance due to investments in health care infrastructure, laboratory modernization, and science in general. Organizations that concentrate on technological innovation, regulatory compliance, employee training, and partnerships will be in a better position to increase their service offering and develop their businesses.

Molecular pathology laboratories can help in the improvement of the healthcare system in Latin America through innovative operations and strategic planning. In addition, these organizations can make a significant contribution to the healthcare industry through their innovations and proper business practices.

The functional health and wellness market continues to expand as consumers seek products that support their daily health goals through nutrition. People are no longer satisfied with products that only address deficiencies. They seek supplements that fit into active lifestyles and promote energy, digestive health, immune support, cognitive performance and healthy aging. This shift has encouraged companies to develop advanced formulations that combine scientific quality and convenience. Every supplement manufacturer plays a central role in meeting these expectations by creating products that align with changing consumer preferences while maintaining high standards of safety and consistency.

Innovation has become an important driver of growth in functional wellness. Manufacturers continue exploring botanical extracts, probiotics, vitamins, minerals, amino acids and other specialty ingredients that provide targeted health support. They also invest in research to understand how ingredients interact and how delivery systems influence absorption. These efforts allow companies to introduce products that fit different lifestyles while maintaining product effectiveness.

Advancing Product Innovation Through Research

Scientific research forms the foundation of successful supplement development. Manufacturers work with researchers, formulation specialists and quality professionals to translate emerging nutritional knowledge into practical consumer products. This collaborative approach helps identify ingredients with strong scientific support while ensuring formulations remain stable and effective throughout their shelf life.

Ingredient combinations are carefully selected to support specific wellness objectives. Products designed for digestive wellness may combine probiotics with plant based fibers while formulations for healthy aging may include antioxidants and vitamins that contribute to overall wellness. Companies continue refining these combinations as research expands our understanding of nutrition.

Manufacturing technology continues to evolve. Advanced processing systems in modern manufacturing streamline and automate blending, batching, and packaging. Automated systems help minimize production variability, maximizing consistency from batch to batch and creating greater trust and reliability across more product categories.

The established manufacturing capabilities and technologies have enabled delivery formats beyond traditional tablets and capsules. More convenient formats, such as gummies, powders, liquid concentrates, chewables, and functional drink mixes, are more regularly used as consumables. So are formats that integrate wellness routines. Improvements in texture and flavor have led to better systems for maintaining product quality.

Manufacturing regulations help ensure consistency and safety for consumers. This leads manufacturers to create and maintain adequate documentation and to verify all ingredients and their sources. Internal audits and evaluations of all suppliers, along with the continuous monitoring of all processes, help ensure and maintain compliance and integrity. This is especially useful for navigating upcoming and evolving manufacturing and processing regulations.

Building Consumer Trust Through Quality

Trust remains one of the strongest competitive advantages within the wellness market. Consumers often make purchasing decisions based on brand reputation, ingredient transparency and manufacturing reliability. Companies, therefore, invest heavily in quality assurance systems that demonstrate their commitment to producing dependable supplements.

Every stage of production includes quality checkpoints designed to verify ingredient identity, product consistency and finished product performance. Laboratory testing supports these efforts by confirming that products meet established specifications before reaching retailers and consumers. Traceability systems further strengthen confidence by allowing manufacturers to monitor ingredients from sourcing through final distribution.

Clear labeling also contributes to consumer confidence. Well-designed labels explain ingredient content, serving recommendations and storage instructions in an understandable format. Educational materials help consumers make informed decisions while encouraging responsible supplement use as part of an overall wellness routine.

Expanding the Future of Functional Wellness

The development of functional wellness will require a commitment to innovation and a commitment to the science behind wellness. Manufacturers are beginning to offer personalized nutrition that incorporates dietary preferences, wellness goals, and lifestyle choices. This offers greater flexibility in product options and is intended to appeal to broader groups of consumers.

Research into the ingredients that promote wellness is progressing, and so are the product options available to manufacturers and consumers. Plant-derived compounds, additional nutrients, and more fermented products will increasingly be added to available options as understanding of the science continues. Caution is important when considering the use of these innovations in commercial products.

Advancements in the global supply chain will positively impact the development of new products. Fermentation and cultivation from many different regions will provide high quality, diverse, and reliable ingredients. This benefits both consumers and manufacturers.

Product and service innovations will fail without consumer education. People want to be educated on how the ingredients and products will function. Clear communication and science-based honesty will promote long-term relationships with customers.

Education will remain equally important as product innovation. Consumers increasingly value information that explains ingredient functions, recommended usage and realistic wellness expectations. Companies that communicate clearly while supporting scientific credibility strengthen long term customer relationships and encourage informed purchasing decisions.

As the wellness industry continues evolving, manufacturers will remain essential partners in helping consumers pursue healthier lifestyles. Their commitment to research, quality, transparency and responsible production supports steady market growth while encouraging confidence in nutritional products. A dedicated supplement manufacturer that combines scientific expertise with reliable manufacturing practices can continue delivering solutions that meet changing wellness needs. Through ongoing innovation responsible sourcing and a strong commitment to quality the industry is well positioned to support the expanding functional health and wellness market for years to come.

Healthcare is transforming from a one-size-fits-all approach to a precise, personalized, and predictive model powered by genetic testing. Once confined to the specialized realms of academic research or the diagnosis of rare hereditary conditions, genomic insights are rapidly becoming a cornerstone of clinical practice and pharmaceutical innovation. Within this global shift, Latin America is emerging as a particularly significant arena, demonstrating how genetic understanding is evolving from a scientific niche into a clinical necessity.

The Expansion of Clinical Utility From Rare Disease to Common Practice

The initial applications of genetic testing were highly focused. They were the tools of specialists, used to confirm suspected monogenic disorders—conditions caused by a single gene mutation. While critically important to affected families, this application represented only a narrow slice of healthcare. The sea change we are witnessing today is driven by the expansion of genetic insights into virtually every corner of medicine, particularly in two major fields: oncology and pharmacogenomics.

In oncology, genetic testing has become indispensable. The understanding that cancer is a disease of the genome has shifted the entire diagnostic and therapeutic framework.³ Rather than classifying a tumor based solely on its location in the body (e.g., breast, lung, colon), clinicians now routinely use genetic sequencing to identify the specific driver mutations fueling its growth. This molecular profiling enables the selection of targeted therapies designed to attack the cancer's specific genetic vulnerabilities. This approach leads to more effective treatment strategies. It moves beyond the blunt-instrument tactics of traditional chemotherapy, heralding a new era of personalized cancer care that is gaining significant traction at Latin America's major medical centers.

Pharmacogenomics (PGx) provides the scientific basis for "the right drug, for the right patient, at the correct dose. It is a well-established fact that medications do not work the same way for everyone; some people experience severe side effects, while others derive no benefit at all.⁷ Genetic testing can now identify variations in genes—particularly those coding for metabolic enzymes—that predict these responses.

Clinicians are increasingly using PGx panels before prescribing common medications, including certain antidepressants, cardiovascular drugs, and pain relievers. This simple genetic insight can prevent adverse drug reactions, improve the efficacy of a treatment from day one, and save valuable time and resources previously lost to trial-and-error prescribing. As awareness and implementation grow, pharmacogenomic testing is setting a new standard of care, ensuring safety and efficacy are personalized to a patient's genetic profile.

Reshaping the Pharmaceutical Pipeline: A New Blueprint for Drug Discovery

The impact of genetic testing extends well beyond clinical practice, fundamentally reshaping the pharmaceutical industry's research and development (R&D) paradigm. The integration of human genomics is now systematically reducing these risks and ushering in a new era of precision medicine. Genetic data serves as a powerful instrument for target identification and validation—by analyzing large-scale genomic datasets, researchers can uncover genes and biological pathways directly associated with disease. This “genetics-first” approach ensures that potential drug targets are validated by human biology rather than theoretical models, substantially increasing the likelihood of clinical success.

With genetic testing, trials can now be “biomarker-driven,” enrolling patients based on their genetic profiles or the molecular characteristics of their disease. This approach enhances efficacy by focusing on individuals most likely to respond to treatment, enabling smaller, faster, and more statistically robust trials. It also drives the parallel development of companion diagnostics—genetic tests designed to identify patients eligible for a specific therapy—thereby embedding precision testing into the standard of care.

This genomics-driven R&D model is no longer conceptual but an active reality shaping pharmaceutical pipelines worldwide. Companies are increasingly investing in targeted therapies for genetically defined populations, a strategy that enhances success rates, accelerates development timelines, and ultimately delivers more effective treatments from the laboratory to the patient’s bedside.

The Latin American Context

The integration of genetic medicine in Latin America is home to one of the world's most diverse and admixed populations. Generic models of disease and drug response, which are primarily based on studies of populations of European descent, are often incomplete or inaccurate when applied to individuals in Latin America. The specific genetic variants and frequencies found within these diverse populations can significantly influence disease susceptibility, progression, and response to treatment.

Recognizing this, there is a growing momentum within the region's scientific community to build genomic databases and research initiatives that reflect this unique diversity. By studying its own populations, Latin America can uncover novel genetic insights relevant to its people, driving the development of more effective and equitable precision medicine strategies. This localized research is crucial for identifying population-specific biomarkers and tailoring pharmacogenomic guidelines to ensure that drug therapies are optimized for all population segments. This focus on ancestral diversity is not only improving healthcare within the region but is also contributing invaluable knowledge to the global understanding of human genetics, making Latin America an indispensable partner in the future of genomic medicine.

The era of genetic testing as a peripheral or niche tool is decisively over. It has become a fundamental driver of medical progress, acting as the bridge between basic science and individualized patient care. In Latin America, this technology is not just being adopted; it is being integrated into the very fabric of the healthcare ecosystem. It empowers clinicians to make more precise diagnoses, enabling personalized cancer therapies and making drug prescriptions safer and more effective. Concurrently, it is providing the pharmaceutical industry with the map and compass needed to navigate the complex world of drug discovery, leading to more innovative and successful pipelines. The journey from niche to necessity is reshaping the future of health, and Latin America is emerging as a vital center in this global transformation.

Through this article, Mitchell emphasizes the rapid shift of surgical procedures from traditional hospital settings to ambulatory surgery centers (ASCs), highlighting their cost efficiency and the technological advancements positioning ASCs as the future of modern surgical care.

The healthcare industry is undergoing a fundamental shift as surgical procedures continue transitioning from traditional inpatient settings to ambulatory surgery centers (ASCs). This site-of-care transformation is driven by rising healthcare costs, technological advancements and evolving payer incentives that favor outpatient settings. As healthcare leaders search for innovative ways to improve efficiency and affordability, ASCs have emerged as a critical solution in modern surgical care.

Today, there are more than 6,000 ASCs across the United States, performing over 23 million procedures annually (MedPAC, 2023). These centers are not only reshaping how surgery is delivered but also expanding their capabilities to include more complex procedures, such as total joint replacements, spine surgeries and select cardiovascular interventions. With continued advances in surgical techniques, anesthesia and digital health, ASCs are positioned to become the dominant setting for many procedures traditionally performed in hospitals. The question is no longer whether outpatient surgery will continue growing, but rather how fast and how far the shift will go.

The Evolution of Outpatient Surgery

The concept of ambulatory surgery dates to the 1970s when physicians sought a more efficient and cost-effective alternative to hospital-based procedures. Over the decades, improvements in anesthesia, minimally invasive techniques and enhanced recovery protocols have allowed more procedures to be performed safely in outpatient settings (ASCA, 2023).

Initially, ASCs focused on low-acuity procedures, such as cataract surgeries and endoscopies. However, recent policy changes have enabled a broader range of surgeries to shift to ASCs. The Centers for Medicare & Medicaid Services (CMS) has expanded its list of ASC-approved procedures, including total knee arthroplasty, cardiac catheterization and select spine surgeries (CMS, 2024). These changes signal a growing recognition of ASCs’ ability to provide high-quality, cost-effective surgical care.

[QUOTE1_Replace]

The increasing shift of surgeries from hospital operating rooms to ASCs is driven by multiple factors. Patients are seeking more convenient and affordable options, insurers are incentivizing cost-effective care settings and surgeons are looking for more control over their practice environments. The alignment of these interests has fueled the rapid expansion of ASCs and their role in the healthcare ecosystem.

The Business Case for ASCs

One of the most compelling reasons for the growth of ASCs is their cost efficiency. ASCs typically perform procedures at 30 to 50 percent lower costs than hospital outpatient departments (HOPDs), primarily due to lower facility fees, streamlined workflows and reduced administrative burdens (Health Affairs, 2022). These savings benefit not only payers and employers but also patients, who experience lower outof-pocket expenses.

Despite the cost advantages, ASCs have faced reimbursement challenges. Historically, CMS and private insurers have reimbursed ASCs at lower rates than hospital outpatient departments for the same procedures. Currently, ASCs receive approximately 80 percent of the reimbursement that hospitals receive for identical services (MedPAC, 2023). While policymakers are beginning to recognize the value that ASCs bring to the healthcare system, reimbursement disparities remain an ongoing concern.

Payer strategies are also evolving in ways that favor ASCs. Direct-to-employer contracts and bundled payment arrangements are gaining popularity as employers seek to control healthcare costs. By steering employees toward ASCs for procedures such as joint replacements and colonoscopies, employers can reduce expenses while maintaining high-quality care (KFF, 2023).

Expanding Surgical Specialties in ASCs

The range of procedures performed in ASCs continues to expand. Total joint replacements have become one of the fastest-growing areas in outpatient surgery, with a more than 200 percent increase in ASC-based procedures over the past five years (AAOS, 2023). Advances in minimally invasive techniques, improved pain management protocols and enhanced recovery after surgery (ERAS) programs have made it possible for patients to undergo joint replacements and return home the same day.

Spine surgery is another area experiencing significant growth in ASCs. Minimally invasive spine procedures, including microdiscectomies and fusions, are increasingly being performed in outpatient settings. The ability to manage post-operative pain effectively has been a key factor in this shift, allowing patients to recover in the comfort of their homes rather than spending extended time in hospitals (Becker’s ASC Review, 2023).

The cardiology field is also beginning to embrace outpatient surgery. With CMS now approving select cardiac procedures for ASCs, including percutaneous coronary interventions (PCI) and pacemaker placements, the potential for expansion in this specialty is substantial (CMS, 2024). As technology advances and reimbursement policies continue to evolve, cardiovascular interventions are likely to become a larger part of ASC services.

Technology and Innovation Driving ASC Growth

Technological advancements are playing a crucial role in the transformation of outpatient surgery. Robotics and minimally invasive surgical techniques are now being integrated into ASCs, improving precision, reducing recovery times and enhancing patient outcomes. While robotic-assisted surgery was once confined to large hospitals, it is increasingly being adopted in ASCs, particularly in orthopedic and spine procedures (Becker’s ASC Review, 2023).

Digital health solutions are also contributing to the growth of ASCs. Telehealth and remote patient monitoring are improving preoperative assessments and postoperative care, reducing complications and enhancing patient engagement. Wearable technology allows surgeons to track recovery metrics in real time, enabling early intervention if complications arise (Health Affairs, 2022).

Artificial intelligence (AI) is also beginning to shape decision-making in ASCs. AI-driven analytics help optimize patient selection, predict surgical risks and improve operating room efficiency. Machine learning algorithms are also being used to refine scheduling processes, reducing downtime and increasing case volumes (AMA, 2023).

The business of outpatient ambulatory surgery is at a critical inflection point. ASCs have proven their value in delivering efficient, high-quality and cost-effective care, and their role will only continue to grow. However, addressing challenges related to reimbursement, staffing and regulation will be essential to ensuring their long-term success.

As the healthcare industry moves further toward value-based care, ASCs will become the cornerstone of modern surgical delivery. Their ability to provide high-quality outcomes at lower costs makes them not just a preferred alternative to hospitals, but the future of surgical care itself.

The term ‘pharmacogenomics’ emerged in the early 2000s to encompass the broader study of how genetic variations influence drug response, including not only drug metabolism but also drug targets and pharmacodynamics. Advances in genomic technologies and bioinformatics have accelerated the discovery of genetic variants associated with response to a wide range of drugs.

Surveillance of drug safety concerning individual genetic variances in drug metabolism is key for pharmacogenomics.

Healthcare professionals may effectively mitigate risks associated with genetic variations and drug response, ultimately improving the quality of patient care and treatment outcomes. It involves a multidisciplinary approach that integrates genetics, pharmacology, epidemiology, and regulation to ensure the safe and effective use of drugs in genetically diverse populations.

History of Pharmacogenomics

In the 1950s-1970s studies in ‘pharmacogenetics’ focused on genetic variations and their influence on drug responses. During this time, researchers focused on identifying genetic variants associated with drug metabolism pathways, such as those involving drug-metabolizing enzymes like cytochrome P450.

In 2003 the completion of the Human Genome Project marked a significant milestone in the field of pharmacogenomics. This project provided a comprehensive map of the human genome, facilitating the identification of genetic variants associated with drug response and laying the foundation for personalized medicine approaches.

Role of Pharmacovigilance in Pharmacogenomics

Some key aspects of patient safety monitoring in pharmacogenomics include the collection and analysis of adverse drug reactions (ADRs) associated with pharmacogenomic factors. Monitoring the results of genetic testing allows healthcare providers to tailor treatment schemes to individual patient profiles. Genetic testing (preventive or reactive) may be conducted to identify patients who may be at higher risk of adverse drug reactions or treatment failure due to specific genetic variations. Gene therapy clinical systems integrated into electronic health record systems can provide real-time guidance to healthcare providers based on patients' genetic profiles. These systems can alert providers to potential drug-gene interactions, recommend alternative medications, or suggest dosage adjustments to minimize the risk of adverse events. Training programs can enhance patient safety by ensuring the appropriate use of genetic information in treatment planning.

[QUOTE1_Replace]

Deep research and surveillance efforts are essential for identifying new pharmacogenomic associations, assessing the clinical validity and utility of genetic testing, and monitoring long-term safety outcomes in realworld patient populations. Largescale studies and pharmacovigilance initiatives contribute to our understanding of the safety implications of pharmacogenomics.

Patient engagement plays an active role in monitoring their own safety in pharmacogenomics raising awareness about the importance of genetic testing and targeting a personalized treatment.

Challenges for Pharmacogenomics

Integration into clinical workflows from cross-functional healthcare providers qualified to interpret genetic test results and incorporate them into treatment decisions. Additionally, electronic health record systems must be adapted to accommodate pharmacogenomic data. Data privacy and security, pharmacogenomic testing generates sensitive genetic information that raises concerns about patient privacy and data security. The cost-effectiveness of testing and reimbursement models need to be carefully evaluated.

Challenges for Applicability of Pharmacovigilance in Pharmacogenomics

Genetic testing integration into pharmacovigilance practices allows for personalized drug therapy approaches. Generation of regulatory guidelines for ‘Pharmacogenomics and Pharmacovigilance’ are required to evaluate the safety and efficacy of pharmacogenomicbased therapies, and monitor post-market safety through pharmacovigilance activities such as the assessment and validation of genetic variations of the adverse drug reactions (ADRs) associated with genetic biomarkers specific to drug responses considering pharmacogenomic factors. Post-marketing surveillance in real-world populations assessing the risk of adverse events associated with specific drugs in individuals with certain genetic profiles is the key to aiming risk assessment and its management considering new associations between genetic variations and drug responses. The vision of consolidation of key data and collaboration among stakeholders shall improve understanding of the impact of genetic variations on drug safety and efficacy.

Future of Pharmacogenomics and Patient Safety

Overall, the potential of pharmacogenomics is bright, with the potential to significantly improve patient outcomes, reduce healthcare costs, and advance the practice of personalized and precise medicine. This personalized approach can improve treatment outcomes by minimizing adverse drug reactions and optimizing efficacy. Patients may need to understand the implications of their genetic results on drug therapy decisions for shared decisionmaking with their healthcare providers.

Pharmacogenomic testing will be more accessible and affordable with AI advances in sequencing technology and bioinformatics. Large-scale population-level studies, such as biobanks and genome-wide association studies may generate vast amounts of genetic data that may be used to identify and improve new pharmacogenomic associations. These studies will further enhance understanding of the genetic factors influencing drug response.

Advances in pharmacogenomics are driving the development of targeted therapies designed to treat diseases based on specific genetic mutations or variations. Healthcare providers may be selecting the most appropriate drug and dose for individual patients based on their genetic makeup. Pharmacogenomics has the potential to shift medicine towards a more preventative model by identifying individuals at higher risk of adverse reactions to specific drugs before they are prescribed.

At the end of 2020, amid the COVID Pandemic, my department was celebrating a win during what had been a very difficult year.    Despite clinic closures, a move to virtual visits, parents’ fears about bringing their kids out to public settings, and more, we had somehow managed to provide routine vaccinations to as many children in 2020 as in 2019.    This was before COVID vaccinations provided the confidence that brought many families back into Primary Care, so the fact that we were able to achieve this success despite the pandemic was cause for celebration.   It took a lot of effort, including vaccination tents, community events, replacing unused sick visit slots with more well visits, and copious amounts of texting and phone calls and patient portal messages and emails.   A lot of outreach.    More than we had ever done before.    

As the Director of Analytics and Technology for our Value-Based Services Organization at Nemours Children’s Health, my role in this work was to lead the team that identified the populations to target and help coordinate the messaging.    Active primary care patients, with a gap in care, not deceased, not contraindicated, XYZ age range, no “do not contact” communication preference, etc.  Our lead data analyst had a “rinse and repeat” query written to check all of the boxes for the different communication modalities, and filter the lists by geography/PCP/payer based on the specific gap in the care we were tackling at the time and clinic capacity.   Our job was also to measure and trend our performance for the HEDIS- related “Gap in Care” measures.    And by year-end we were celebrating.   We had improved our vaccination rate for the flu from under 38% to over 42% by year-end when compared to 2019.  This meant that an additional 5000 children had documented flu vaccines in 2020 compared to 2019 despite the Pandemic!  A win for sure (Note:  flu season runs from July to June, but we measure our progress at year-end because we typically administer the majority of our flu vaccines in the Fall before the Holidays).

By the end of 2020 we had hit 4 out of 5 of our prevention goals for the year, projected great scores and payouts from our Pay-for-Performance (P4P) contracts, and started the poster-and-conference submissions work to talk about how we did it all.   Soon after I was invited by two Nemours executives Dr. Kara Odom Walker EVP and Chief Population Health Officer, and Cindy Bo, SVP Delaware Valley Strategy to help support the creation of a new Health Equity Dashboard for Nemours Children’s Health, modeled after the great work by Children’s Minnesota.    After much debate, analysis, consideration and reconsideration we chose flu vaccination rate as one of our first three equity measures to examine across populations.   We knew there were disparities between populations, with a much lower vaccination rate among our African-American patients, so it seemed like a prime candidate.  The data was relatively easy to gather - it could be drilled down by location and physician, and the N was high – all good characteristics for an initial measure to learn from.   What we were not expecting from this equity analysis was to find that our great success during the 2020 flu season, built upon repeated texting, emailing and portal messages, did not result in improvements for our African-American patients.   In fact, despite the overall rate improvement, our disparity in flu vaccination rates for African-American patients actually got worse.

The Christ Hospital Health Network is a community-based health system comprised of both an inpatient facility and a variety of outpatient clinics and surgery centers.  Beginning in 2019, it implemented and scaled its ambulatory pharmacy program to include coverage across multiple practice areas, including primary care, orthopedics, oncology, and cardiology.  In addition, the program is pioneering comprehensive pharmacogenomic testing in the Cincinnati, OH, area.  Using novel practice models and advanced clinical decision support tools (CDSTs), the network is leading the way in integrated pharmacy care.

What is pharmacogenomics, and how does technology play a role?

Pharmacogenomics evaluates how a patient’s genes may impact the way they respond to medications, including efficacy and metabolism.  For example, patients may have a mutation in an enzyme that breaks down a particular drug.  If that mutation causes a loss of function for that enzyme, the patient will be a poor metabolizer of that drug and may encounter higher than desired drug levels.  This can lead to increased side effects and toxicity.  Conversely, if a patient has a higher than usual metabolism of drugs, they may not achieve sufficient drug levels to treat their condition.

Pharmacogenomics is a relatively new area of practice for most providers.  While the science and data behind pharmacogenomics have long been available, clinical implementation has been a struggle.  Plagued by historically long turnaround times, a lack of gene panel standardization, and a deficit in provider education, it has been an uphill battle to enmesh pharmacogenomics with everyday practice.

Thankfully, as technology has advanced, the processing speed of genetic testing has also greatly improved.  Comprehensive pharmacogenomic testing can be returned in a matter of weeks, and single gene testing can be run in a matter of hours.  In practice, this means that results can often be returned before medications are started, and any genetic interactions can be actively incorporated into the patient's therapy plan.

Providers have struggled with the varied gene panels and laboratories that are available.  Many labs will report on a small number of genes or report on only a small number of affected medications, often restricted by therapeutic area.  While easily digestible for the provider, this provides a false sense of confidence.  Providers may not realize that many indicated genes may not be tested or that interactions outside of a panel's specific therapeutic area may not be reported.  For example, if a patient receives testing for psychiatric pharmacogenomics, even if an identified gene mutation affects another drug used in cardiology, the provider would only be informed on psychiatric drug-gene interactions.  This leaves a great deal of risk for adverse effects beyond the targeted clinical area(s).  Exclusive selection of a panel that includes all guideline-indicated genes and is therapeutically agnostic removes such risk.  This has been the strategy of The Christ Hospital Health Network.  Providers no longer must search for specific panels and laboratories to find the information they are seeking but can select a single, easily located order that covers essentially all indicated genes and reports directly into the electronic health record (EHR) and CDST, where pharmacists work across the care team to optimize medication management.

[QUOTE1_Replace]